0 Ratings

ID

14118

Description

Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management; ODM derived from: https://clinicaltrials.gov/show/NCT01908075

Link

https://clinicaltrials.gov/show/NCT01908075

Keywords

  1. 3/30/16 3/30/16 -
Uploaded on

March 30, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :


    No comments

    In order to download data models you must be logged in. Please log in or register for free.

    Eligibility Asthma NCT01908075

    Eligibility Asthma NCT01908075

    1. StudyEvent: Eligibility
      1. Eligibility Asthma NCT01908075
    Inclusion Criteria
    Description

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693
    aged: 18-80 years 61-80 years to be non-smokers only
    Description

    Age | Non-smoker

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0001779
    UMLS CUI [2]
    C0337672
    evidence of asthma: a diagnostic code for asthma or two scripts for asthma..
    Description

    Asthma

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0004096
    baseline fp/sal therapy: ≥2 prescription for ics/laba therapy as fp/sal
    Description

    fluticasone | salmeterol | Therapeutic procedure | inhaled steroids | Adrenergic beta-2 Receptor Agonists | Therapeutic procedure

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0082607
    UMLS CUI [1,2]
    C0073992
    UMLS CUI [1,3]
    C0087111
    UMLS CUI [2,1]
    C2065041
    UMLS CUI [2,2]
    C2936789
    UMLS CUI [2,3]
    C0087111
    evidence of continuing therapy: include only patients who receive ≥2 prescriptions for the therapy under study during the outcome year (i.e. ≥1 prescription at the index date and ≥1 other). uk average is 3-4 prescriptions refilled per year, so ≥2 ensures capture of "real-life" data.
    Description

    Continuous therapeutic procedure | prescription

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0087111
    UMLS CUI [1,2]
    C0549178
    UMLS CUI [2]
    C1521941
    evidence of switching for economic reasons: fp/sal patients from practices with ≥5 switches to fostair in a 3 month period to minimise data taken from switching of anomalous patients; optimal practices for inclusion are those switching "wholesale" for economic reasons.
    Description

    Therapy change | fluticasone salmeterol

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C3665894
    UMLS CUI [2,1]
    C0082607
    UMLS CUI [2,2]
    C0073992
    UMLS CUI [2,3]
    C0087111
    Exclusion Criteria
    Description

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    any chronic respiratory disease other than asthma
    Description

    Chronic disease of respiratory system

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0264220
    UMLS CUI [2]
    C0004096
    are receiving maintenance oral steroid therapy during baseline period
    Description

    Oral steroid therapy

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0001617
    UMLS CUI [1,2]
    C0087111

    Similar models

    Eligibility Asthma NCT01908075

    1. StudyEvent: Eligibility
      1. Eligibility Asthma NCT01908075
    Name
    Type
    Description | Question | Decode (Coded Value)
    Data type
    Alias
    Item Group
    C1512693 (UMLS CUI)
    Age | Non-smoker
    Item
    aged: 18-80 years 61-80 years to be non-smokers only
    boolean
    C0001779 (UMLS CUI [1])
    C0337672 (UMLS CUI [2])
    Asthma
    Item
    evidence of asthma: a diagnostic code for asthma or two scripts for asthma..
    boolean
    C0004096 (UMLS CUI [1])
    fluticasone | salmeterol | Therapeutic procedure | inhaled steroids | Adrenergic beta-2 Receptor Agonists | Therapeutic procedure
    Item
    baseline fp/sal therapy: ≥2 prescription for ics/laba therapy as fp/sal
    boolean
    C0082607 (UMLS CUI [1,1])
    C0073992 (UMLS CUI [1,2])
    C0087111 (UMLS CUI [1,3])
    C2065041 (UMLS CUI [2,1])
    C2936789 (UMLS CUI [2,2])
    C0087111 (UMLS CUI [2,3])
    Continuous therapeutic procedure | prescription
    Item
    evidence of continuing therapy: include only patients who receive ≥2 prescriptions for the therapy under study during the outcome year (i.e. ≥1 prescription at the index date and ≥1 other). uk average is 3-4 prescriptions refilled per year, so ≥2 ensures capture of "real-life" data.
    boolean
    C0087111 (UMLS CUI [1,1])
    C0549178 (UMLS CUI [1,2])
    C1521941 (UMLS CUI [2])
    Therapy change | fluticasone salmeterol
    Item
    evidence of switching for economic reasons: fp/sal patients from practices with ≥5 switches to fostair in a 3 month period to minimise data taken from switching of anomalous patients; optimal practices for inclusion are those switching "wholesale" for economic reasons.
    boolean
    C3665894 (UMLS CUI [1])
    C0082607 (UMLS CUI [2,1])
    C0073992 (UMLS CUI [2,2])
    C0087111 (UMLS CUI [2,3])
    Item Group
    C0680251 (UMLS CUI)
    Chronic disease of respiratory system
    Item
    any chronic respiratory disease other than asthma
    boolean
    C0264220 (UMLS CUI [1])
    C0004096 (UMLS CUI [2])
    Oral steroid therapy
    Item
    are receiving maintenance oral steroid therapy during baseline period
    boolean
    C0001617 (UMLS CUI [1,1])
    C0087111 (UMLS CUI [1,2])

    Please use this form for feedback, questions and suggestions for improvements.

    Fields marked with * are required.

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial